"Zepbound: Eli Lilly's FDA-approved weight loss drug making waves in the market"

Eli Lilly's new weight loss drug, Zepbound, has been approved by the FDA and is expected to be available shortly after Thanksgiving. Zepbound belongs to a class of medications called GLP-1 agonists, which have gained popularity in recent years. In clinical trials, Zepbound helped people lose an average of 52 pounds, rivaling the weight loss results of bariatric surgery. The drug contains tirzepatide, which mimics hormones that reduce food cravings and improve the breakdown of sugar and fat. Zepbound is approved for adults with a BMI of at least 30 or a BMI of 27 with another weight-related condition. However, the high cost of the drug may be a barrier for many people. Side effects include gastrointestinal problems, and pregnant individuals should not take the medication. Zepbound is expected to be available for prescription in the U.S. after Thanksgiving.